Asparkam-Pharmak

General characteristics. Structure:

1 ml of solution contains:

active ingredients: magnesium asparaginate of 40 mg (3,37 mg of magnesium), potassium asparaginate of 45,2 mg (10,33 mg of potassium);

excipients: sorbite (E 420), water for injections.

Pharmacological properties:

Pharmacodynamics. Drug belongs to the medicines regulating metabolic processes. Magnesium activates sodium - potassium ATP-ase owing to what the intracellular content of sodium decreases and intake of potassium in a cell increases. At decrease in concentration of sodium in a cell sodium-calcium exchange in unstriated muscles of vessels is slowed down that conducts to their relaxation, potassium ions stimulate synthesis of ATP, a glycogen, proteins, acetylcholine; potassium and magnesium support polarization of cellular membranes. Asparaginate promotes receipt of ions in a cell and takes part in energy balance. The antiarrhytmic effect is implemented thanks to ability of drug to eliminate an imbalance of electrolytes, to reduce excitability and conductivity of a myocardium.

Pharmacokinetics. It is not studied.

Pharmaceutical characteristics

Main physical and chemical properties: transparent colourless or slightly yellowish liquid.

Incompatibility.

Not to mix drug with other medicines, except for the solvents specified in the section "Route of Administration and Doses".

Indications to use:

For additional therapy at chronic heart diseases (at heart failure, during the postinfarction period), disturbances of a heart rhythm, first of all ventricular arrhythmias.

Additional therapy at treatment by foxglove drugs.

Route of administration and doses:

Drug is intended only for intravenous administration. Asparkam-Pharmak the adult to enter slowly intravenously kapelno 10-20 ml (to part contents of ampoules in 50-100 ml sterile 0,9% of solution of sodium of chloride or 5% of solution of glucose). If necessary the dose can be repeated in 4-6 hours. Drug is suitable for a combination therapy.

The course of treatment is defined by the doctor.

Features of use:

Use during pregnancy or feeding by a breast

Still it was not reported about emergence of any danger at use of drug for this category of patients. Use of drug is possible in that case when the expected advantage for mother exceeds potential risk for a fruit or the child.
Children

Experience drug use to children insufficient therefore this category of patients cannot apply Asparkam-Pharmak.

Bystry introduction can cause a hyperemia of the person.

Asparkam-Pharmak as the drug containing potassium and magnesium patients need to apply with care with a myasthenia гравис; at states which can lead to a hyperpotassemia, such as acute dehydration, widespread damage of fabrics, in a particular at heavy burns. It is regularly recommended to investigate the level of electrolytes in blood serum at this category of patients.
Ability to influence speed of response at control of motor transport or work with other mechanisms

Drug does not influence management of transport.

Side effects:

At bystry administration of drug manifestations of symptoms of a hyperpotassemia or a gipermagniyemiya are possible.

Interaction with other medicines:

At simultaneous use of Asparkam-Pharmak with kaliysberegayushchy diuretics or APF inhibitors the risk of development of a hyperpotassemia increases (in this case it is necessary to control potassium level in a blood plasma). Asparkam-Pharmak reduces sensitivity to cardiac glycosides.

Contraindications:

Hypersensitivity to active ingredients or to any of drug excipients. An acute and chronic renal failure, Addison's disease, an atrioventricular block ІІІ degrees, cardiogenic shock (with a systolic arterial pressure <90 mm of mercury.).

Overdose:

At bystry jet introduction or at administration of drug in doses which considerably exceed therapeutic the hyperpotassemia and a gipermagniyemiya develop.

Hyperpotassemia symptoms: general weakness, paresthesias, disturbance of conductivity of a myocardium, paralysis, bradycardia. Very high potassium concentration in plasma can lead to death as a result of oppression of cordial activity, arrhythmia or a cardiac standstill.

Gipermagniyemiya symptoms: nausea, vomiting, diarrhea, drowsiness, hypotension, weakness, the muffled speech, doubling in eyes, a disorientation, dizziness, bradycardia. At very high concentration of magnesium in plasma the hyporeflexia, neuromuscular blockade, respiratory depression and a cardiac standstill can develop.

In such cases it is necessary to enter calcium a gluconate or Calcii chloridum of 10% 10-40 ml (depending on weight of overdose), to hold events for maintenance of breath and a hemodynamics, symptomatic therapy. In case of a serious poisoning at insufficient efficiency of the listed actions carrying out a hemodialysis is shown.

Storage conditions:

Period of validity 2 years. Not to use drug after the termination of the period of validity specified on packaging. To store in the place protected from light at a temperature from 15 °C to 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

On 5 ml or 10 ml, or 20 ml in an ampoule. On 10 ampoules in a pack.